novo nordisk glp-1 receptor agonist medications Nordisk's weight-loss pill wins FDA approval Novo, Lilly weight-loss drugs should

In a Phase 2b study in people with type 2 diabetes and obesity over 54 weeks, treatment with cotadutide at doses of 100-300 g daily improved some non-invasive markers of NAFLD such as transaminase levels, the FIB-4 index, fatty liver disease fibrosis score (NFS) and fatty liver index (FLI) but fatty liver disease was not assessed directly with liver biopsy

Figure 2 The various aforementioned GLP-1RAs are peptides that are easily hydrolyzed by proteases, thus making their oral use basically ineffective

International journal of biological sciences

10.12688/f1000research.20602.1 [DOI] [PMC free article] [PubMed] [Google Scholar] Richard J

The antithrombotic properties of GLP-1R agonists are complementary to those offered by platelet antagonists (aspirin, clopidogrel) and are not associated with an increased bleeding risks [99, 100]

Appetite suppression from GLP-1 or GLP-1/GIP therapy can make this deficiency more likely without intentional meal planning